On Inflammatory Hypothesis of Depression: What is the Role of IL-6 in the Middle of the Chaos?

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2021 Feb 17

PMID 33593388

Citations 76

Authors

Elnaz Roohi

Nematollah Jaafari

Farshad Hashemian

Affiliations

Soon will be listed here.

Abstract

Many patients with major depressive disorder (MDD) are reported to have higher levels of multiple inflammatory cytokines including interleukin 6 (IL-6). Recent studies both pre-clinical and clinical have advocated for the functional role of IL-6 in development of MDD and suggested a great potential for targeting this cytokine to open new avenues in pharmacotherapy of depression. The purpose of the present narrative review was to provide an integrated account of how IL-6 may contribute to development of depression. All peer-reviewed journal articles published before July 2020 for each area discussed were searched by WOS, PubMed, MEDLINE, Scopus, Google Scholar, for original research, review articles, and book chapters. Publications between 1980 and July 2020 were included. Alterations in IL-6 levels, both within the periphery and the brain, most probably contribute to depression symptomatology in numerous ways. As IL-6 acts on multiple differing target tissues throughout the body, dysregulation of this particular cytokine can precipitate a multitude of events relevant to depression and blocking its effects can prevent further escalation of inflammatory responses, and potentially pave the way for opening new avenues in diagnosis, treatment, and prevention of this debilitating disorder.

Citing Articles

Fibromyalgia, Depression, and Autoimmune Disorders: An Interconnected Web of Inflammation.

Sedda S, Cadoni M, Medici S, Aiello E, Erre G, Nivoli A Biomedicines. 2025; 13(2).

PMID: 40002916 PMC: 11853372. DOI: 10.3390/biomedicines13020503.

Increased Interleukin-6 Levels in Responders with Treatment-Resistant Depression After Bright Light Therapy.

Kosanovic Rajacic B, Sagud M, Begic D, Nikolac Perkovic M, Kozmar A, Rogic D Biomolecules. 2025; 15(2).

PMID: 40001598 PMC: 11852636. DOI: 10.3390/biom15020295.

Food Insecurity and Coping Mechanisms: Impact on Maternal Mental Health and Child Malnutrition.

Rahi B, Al Mashharawi F, Harb H, El Khoury-Malhame M, Mattar L Nutrients. 2025; 17(2).

PMID: 39861459 PMC: 11768350. DOI: 10.3390/nu17020330.

Interleukin-6 in epilepsy and its neuropsychiatric comorbidities: How to bridge the gap.

Chen X, Zhang S, Gao S, Xu M World J Psychiatry. 2025; 15(1):100297.

PMID: 39831011 PMC: 11684222. DOI: 10.5498/wjp.v15.i1.100297.

Functional resting state connectivity is differentially associated with IL-6 and TNF-α in depression and in healthy controls.

Schmitz C, Sammer G, Neumann E, Blecker C, Grunder G, Adolphi H Sci Rep. 2025; 15(1):1769.

PMID: 39800770 PMC: 11725594. DOI: 10.1038/s41598-025-85514-0.

References

Kelly J, Clarke G, Cryan J, Dinan T . Brain-gut-microbiota axis: challenges for translation in psychiatry. Ann Epidemiol. 2016; 26(5):366-72. DOI: 10.1016/j.annepidem.2016.02.008. View

Arango Duque G, Descoteaux A . Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5:491. PMC: 4188125. DOI: 10.3389/fimmu.2014.00491. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Irwin M, Miller A . Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007; 21(4):374-83. DOI: 10.1016/j.bbi.2007.01.010. View

Baudry A, Pietri M, Launay J, Kellermann O, Schneider B . Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response. Front Neurosci. 2019; 13:91. PMC: 6379337. DOI: 10.3389/fnins.2019.00091. View

Chocano-Bedoya P, Mirzaei F, OReilly E, Lucas M, Okereke O, Hu F . C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression. J Affect Disord. 2014; 163:25-32. PMC: 4029945. DOI: 10.1016/j.jad.2014.03.023. View

Kong E, Sucic S, Monje F, Savalli G, Diao W, Khan D . STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behavior. Sci Rep. 2015; 5:9009. PMC: 5390910. DOI: 10.1038/srep09009. View

Horowitz M, Zunszain P . Neuroimmune and neuroendocrine abnormalities in depression: two sides of the same coin. Ann N Y Acad Sci. 2015; 1351:68-79. DOI: 10.1111/nyas.12781. View

Young E, Haskett R, Grunhaus L, Pande A, Weinberg V, Watson S . Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Arch Gen Psychiatry. 1994; 51(9):701-7. DOI: 10.1001/archpsyc.1994.03950090033005. View

10.

Fonseka T, McIntyre R, Soczynska J, Kennedy S . Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs. 2015; 24(4):459-75. DOI: 10.1517/13543784.2014.998334. View

11.

Monje F, Cabatic M, Divisch I, Kim E, Herkner K, Binder B . Constant darkness induces IL-6-dependent depression-like behavior through the NF-κB signaling pathway. J Neurosci. 2011; 31(25):9075-83. PMC: 6623479. DOI: 10.1523/JNEUROSCI.1537-11.2011. View

12.

Muller N, Myint A, Krause D, Weidinger E, Schwarz M . Anti-inflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 42:146-53. DOI: 10.1016/j.pnpbp.2012.11.008. View

13.

Hirschfeld R . History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000; 61 Suppl 6:4-6. View

14.

Gubernatorova E, Gorshkova E, Polinova A, Drutskaya M . IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020; 53:13-24. PMC: 7237916. DOI: 10.1016/j.cytogfr.2020.05.009. View

15.

Felger J, Lotrich F . Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013; 246:199-229. PMC: 3741070. DOI: 10.1016/j.neuroscience.2013.04.060. View

16.

Leighton S, Nerurkar L, Krishnadas R, Johnman C, Graham G, Cavanagh J . Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2017; 23(1):48-58. PMC: 5754468. DOI: 10.1038/mp.2017.205. View

17.

Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G . The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993; 23(2):473-80. DOI: 10.1002/eji.1830230226. View

18.

Galic M, Riazi K, Pittman Q . Cytokines and brain excitability. Front Neuroendocrinol. 2012; 33(1):116-25. PMC: 3547977. DOI: 10.1016/j.yfrne.2011.12.002. View

19.

Schmidt F, Weschenfelder J, Sander C, Minkwitz J, Thormann J, Chittka T . Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015; 10(3):e0121971. PMC: 4363366. DOI: 10.1371/journal.pone.0121971. View

20.

Nishuty N, Khandoker M, Karmoker J, Ferdous S, Shahriar M, Qusar M . Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients. Cureus. 2019; 11(1):e3868. PMC: 6414189. DOI: 10.7759/cureus.3868. View